PVLA Latest Press Releases

-- May 27, 2026 --

Palvella Therapeutics Strengthens QTORIN Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043 Globe Newswire 7:30 AM

-- May 21, 2026 --

Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards Globe Newswire 7:30 AM

-- May 20, 2026 --

Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations Globe Newswire 4:30 PM

-- May 15, 2026 --

Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology Globe Newswire 7:30 AM

-- May 13, 2026 --

Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market Globe Newswire 7:30 AM

-- May 7, 2026 --

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 7:30 AM

-- May 4, 2026 --

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN Rapamycin for Clinically Significant Angiokeratomas Globe Newswire 7:30 AM

-- April 30, 2026 --

Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026 Globe Newswire 7:30 AM

-- April 20, 2026 --

Palvella Therapeutics to Present QTORIN Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026 Globe Newswire 7:30 AM

-- April 13, 2026 --

Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors Globe Newswire 7:30 AM

-- April 7, 2026 --

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales Globe Newswire 7:30 AM

-- March 31, 2026 --

Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update Globe Newswire 7:30 AM

-- March 30, 2026 --

Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations Globe Newswire 7:30 AM

-- March 27, 2026 --

Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting Globe Newswire 10:30 AM

-- March 24, 2026 --

Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 Globe Newswire 7:30 AM

-- March 23, 2026 --

Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services Globe Newswire 7:30 AM

-- March 16, 2026 --

Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin Globe Newswire 7:30 AM

-- March 10, 2026 --

Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations Globe Newswire 7:30 AM

-- March 2, 2026 --

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares Globe Newswire 7:30 AM

-- February 25, 2026 --

Palvella Therapeutics Announces Pricing of Upsized Public Offering Globe Newswire 7:57 PM

-- February 24, 2026 --

Palvella Therapeutics Announces Proposed Public Offering Globe Newswire 4:05 PM

Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations Globe Newswire 6:30 AM

-- February 23, 2026 --

Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations Globe Newswire 5:00 PM

-- February 2, 2026 --

Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis Globe Newswire 7:30 AM

-- January 9, 2026 --

Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies Globe Newswire 7:30 AM

-- January 7, 2026 --

Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs Globe Newswire 7:30 AM